Prenumeration
ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions in Poland, which has been resolved after the quarters end, as the Polish government nearly doubled the import quota for medical cannabis for 2025, driven by rapidly growing demand. As ODI Pharma is the exclusive supply partner to one of the leading pharmaceutical brands in Poland, the Company is expected to capitalize on this rapidly increasing demand. With estimated net sales of SEK 96m by 2025/2026, and with an applied P/S multiple of 2.5x, a potential present value per share of SEK 12.3 (17.4) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on ODI Pharma. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.